This inventor holds 2 USPTO granted patents and 3 EPO patents. Top assignees: Acroimmune Biopharma Co., Ltd., Suzhou Stainwei Biotech Inc.. Active years: 2017-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Jiangsu, CN (2017)
- Suzhou, CN (2022)
Company Filing History:
Years Active: 2017-2022
Title: Yiqing Xu: Innovator in Monoclonal Antibody Development
Introduction
Yiqing Xu is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of biotechnology. He has been instrumental in developing innovative monoclonal antibodies that target critical pathways in cancer treatment. With a total of 2 patents to his name, Xu's work is paving the way for advancements in therapeutic applications.
Latest Patents
Yiqing Xu's latest patents include groundbreaking work on monoclonal antibodies. One of his notable inventions is a monoclonal antibody that antagonizes and inhibits the binding of human PD-1 antigen to its ligand. This patent details the amino acid sequences of the CDR regions in both the light and heavy chain variable regions of the antibody. Another significant patent involves a mouse monoclonal antibody that inhibits the binding of vascular endothelial growth factor (VEGF) to its receptor. This invention also includes a humanized preparation process for the antibody, which can be utilized in pharmaceutical compositions for treating various solid tumors, including colon cancer and breast cancer.
Career Highlights
Throughout his career, Yiqing Xu has worked with notable companies in the biotechnology sector. He has been associated with Acroimmune Biopharma Co., Ltd. and Suzhou Stainwei Biotech Inc., where he has contributed to the development of innovative therapeutic solutions. His expertise in monoclonal antibody technology has positioned him as a key player in the industry.
Collaborations
Yiqing Xu has collaborated with several professionals in his field, including Hongqun Hu and Zui Chen. These collaborations have fostered a productive environment for research and development, leading to advancements in antibody therapies.
Conclusion
Yiqing Xu's contributions to monoclonal antibody development are noteworthy and have the potential to impact cancer treatment significantly. His innovative patents and collaborations highlight his commitment to advancing biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile